When Bonni Goldstein, MD, medical director of Canna-Centers, a group of medical marijuana practices in California, prescribes cannabidiol — a compound extracted from marijuana — to children with epilepsy, she always clarifies to their parents that the long-term risks of the compound are unknown. “It wasn’t available 30 years ago,” she explains. Yet, “every single parent has said to me, ‘Well, I don’t know the long-term effects of the medications my child is taking, and the seizures haven’t stopped. I’d like to give my child the best chance possible.’”
